Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Retatrutide · 17 trials · 18 indications
A composite endpoint includes nonfatal myocardial infarction (MI), nonfatal stroke, cardiovascular (CV) death, or hospitalization or urgent visit due to heart failure (HF).
ESKD is defined as the following individual components: persistent eGFR \<15 mL/min/1.73 m\^2 confirmed by 2 measurements at least 4 weeks apart at the central laboratory, initiation of dialysis for at least 28 days, receiving a kidney transplant. Sustained decline in eGFR (≥40%) will be confirmed by a repeated measure at least 4 weeks after the first result.
The GFR in milliliter/minute per1.73 square meter (mL/min/1.73 m²) using iohexol clearance (mGFR-measured glomerular filtration rate)
Time-to-event of recovery of PG concentration from 48 mg/dL to 70 mg/dL.
Change from baseline in total cDI for comparison of retatrutide with placebo
PK: AUC (0-∞) of Metoprolol
PK: AUC (0-∞) of Metoprolol with Retatrutide
PK: Cmax of Metoprolol
| Arm | Type | Description |
|---|---|---|
| Retatrutide Dose Escalation 1 | EXPERIMENTAL | Participants will receive retatrutide subcutaneously (SC) |
| Retatrutide Dose Escalation 2 | EXPERIMENTAL | Participants will receive retatrutide SC |
| Retatrutide Dose Escalation 3 | EXPERIMENTAL | Participants will receive retatrutide SC |
| Retatrutide Dose 1 | EXPERIMENTAL | Participants will receive retatrutide subcutaneously (SC) |
| Retatrutide Dose 2 | EXPERIMENTAL | Participants will receive retatrutide SC |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo SC |
| Retatrutide | EXPERIMENTAL | Participants will receive Retatrutide subcutaneously (SC) |
| Retatrutide Dose 1 to Retatrutide Dose 2 | EXPERIMENTAL | Participants will receive retatrutide dose 1 administered SC for 80 weeks, then retatrutide dose 2 administered SC for an additional 36 weeks |
| Retatrutide Dose 1 to Placebo | PLACEBO_COMPARATOR | Participants will receive retatrutide dose 1 administered SC for 80 weeks, then placebo administered SC for an additional 36 weeks |
| Tirzepatide | ACTIVE_COMPARATOR | Participants will receive tirzepatide administered SC |
| Retatrutide Dose Level 1 | EXPERIMENTAL | Participants will receive retatrutide administered subcutaneously (SC). |
| Retatrutide Dose Level 2 | EXPERIMENTAL | Participants will receive retatrutide administered SC. |
| Retatrutide Dose Level 3 | EXPERIMENTAL | Participants will receive retatrutide administered SC. |
| Retatrutide Dose 3 | EXPERIMENTAL | Participants will receive retatrutide administered SC. |
| Semaglutide | ACTIVE_COMPARATOR | Participants will receive semaglutide administered SC. |
| Retatrutide Extension Period | EXPERIMENTAL | Participants will receive retatrutide after the placebo-controlled 80 week treatment period for an additional 24 weeks. |
| Name | Type | Description |
|---|---|---|
| Retatrutide | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
| Tirzepatide | DRUG | Administered SC |
| Semaglutide | DRUG | Administered SC. |
| Metoprolol | DRUG | Administered orally |
Inclusion Criteria: * Have a Body Mass Index (BMI) at screening * ≥ 30 kilogram per square meter (kg/m2) OR * ≥ 27 kg/m2 with presence of at least one of the following weight-related conditions at screening: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease ...
Retatrutide is an investigational small molecule being developed for Type 2 Diabetes Mellitus, Obesity, and Overweight or Obesity. It is also being studied in chronic kidney disease with or without Type 2 diabetes. The drug is in Phase 3 clinical development and is not yet approved by regulatory authorities.
Retatrutide is an agonist of the GIPR, GLP1R, and GCGR receptors. It activates these three targets, which are involved in glucose metabolism and appetite regulation. The drug is being studied for its effects on glycemic control and weight management in conditions such as Type 2 diabetes and obesity.
Retatrutide is developed by Eli Lilly and Company, traded on the New York Stock Exchange under the ticker LLY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in multiple indications, including Type 2 diabetes and obesity.
Retatrutide is in Phase 3 clinical development. It is an investigational drug, meaning it has not received FDA approval and is still being studied in clinical trials. Several Phase 3 trials are active, including studies comparing it to semaglutide and placebo in patients with Type 2 diabetes.
Retatrutide is being studied in multiple trials, including NCT06260722, a Phase 3 trial comparing it with semaglutide in Type 2 diabetes patients on metformin. NCT06297603 is a Phase 3 trial in Type 2 diabetes patients with renal impairment. NCT05936151, a Phase 2 trial, examined its effect on renal function in overweight or obese participants with chronic kidney disease.
Yes, Retatrutide is also known by the code name LY3437943. Clinical trial records, such as NCT05936151, refer to the drug as Retatrutide (LY3437943), confirming that both names identify the same investigational compound being developed by Eli Lilly.